Jared M. Sampson

Jared M. Sampson

Auto-generated profile, based on publicly available information

Jared M. Sampson

Department of Biochemistry and Molecular Biophysics, Columbia University, United States; Department of Chemistry, Columbia University, United States; Life Sciences Software, Schrödinger, Inc, United States

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in Neuron
Verified
Journal Article
Closed access
MYMaria V. Yelshanskaya
Maria V. Yelshanskaya
ASAppu K. Singh
Appu K. Singh
JSJared M. Sampson
Jared M. Sampson
CNChamali Narangoda
Chamali Narangoda
MKMaria Kurnikova
Maria Kurnikova
ASAlexander I. Sobolevsky
Alexander I. Sobolevsky

1 June 2012 in Virology
Verified
Journal Article
Closed access
MGMiroslaw K. Gorny
Miroslaw K. Gorny
RPRuimin Pan
Ruimin Pan
CWConstance Williams
Constance Williams
XWXiao-Hong Wang
Xiao-Hong Wang
BVBarbara Volsky
Barbara Volsky
SZSusan Zolla-Pazner
Susan Zolla-Pazner

7 September 2010 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
GBGermán Bou
Germán Bou
ESElena Santillana
Elena Santillana
ASAnjaneyulu Sheri
Anjaneyulu Sheri
ABAlejandro Beceiro
Alejandro Beceiro
JSJared M. Sampson
Jared M. Sampson
JBJohn D. Buynak
John D. Buynak

2 December 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MGMiroslaw K. Gorny
Miroslaw K. Gorny
JSJared Sampson
Jared Sampson
HLHuiguang Li
Huiguang Li
XJXunqing Jiang
Xunqing Jiang
MTMaxim Totrov
Maxim Totrov
XKXiang-Peng Kong
Xiang-Peng Kong
Preferential usage of immunoglobulin (Ig) genes that encode antibodies (Abs) against various pathogens is rarely observed and the nature of their dominance is unclear in the context of stochastic recombination of Ig genes. The hypothesis that restricted usage of Ig genes predetermines the antibody specificity was tested in this study of 18 human anti-V3 monoclonal Abs (mAbs) generated from unrelated individuals infected with various subtypes of HIV-1, all of which preferentially used pairing of the VH5-51 and VL lambda genes. Crystallographic analysis of five VH5-51/VL lambda-encoded Fabs complexed with various V3 peptides revealed a common three dimensional (3D) shape of the antigen-binding sites primarily determined by the four complementarity determining regions (CDR) for the heavy (H) and light (L) chains: specifically, the H1, H2, L1 and L2 domains. The CDR H3 domain did not contribute to the shape of the binding pocket, as it had different lengths, sequences and conformations for each mAb. The same shape of the binding site was further confirmed by the identical backbone conformation exhibited by V3 peptides in complex with Fabs which fully adapted to the binding pocket and the same key contact residues, mainly germline-encoded in the heavy and light chains of five Fabs. Finally, the VH5-51 anti-V3 mAbs recognized an epitope with an identical 3D structure which is mimicked by a single mimotope recognized by the majority of VH5-51-derived mAbs but not by other V3 mAbs. These data suggest that the identification of preferentially used Ig genes by neutralizing mAbs may define conserved epitopes in the diverse virus envelopes. This will be useful information for designing vaccine immunogen inducing cross-neutralizing Abs.

15 December 2016 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
XJXunqing Jiang
Xunqing Jiang
MTMax Totrov
Max Totrov
WLWei Li
Wei Li
JSJared M. Sampson
Jared M. Sampson
CWConstance Williams
Constance Williams
XKXiang-Peng Kong
Xiang-Peng Kong
The V1V2 region of HIV-1 gp120 harbors a major vulnerable site targeted by a group of broadly neutralizing monoclonal antibodies (MAbs) such as PG9 through strand-strand recognition. However, this epitope region is structurally polymorphic as it can also form a helical conformation recognized by RV144 vaccine-induced MAb CH58. This structural polymorphism is a potential mechanism for masking the V1V2 vulnerable site. Designing immunogens that can induce conformation-specific antibody (Ab) responses may lead to vaccines targeting this vulnerable site. We designed a panel of immunogens engrafting the V1V2 domain into trimeric and pentameric scaffolds in structurally constrained conformations. We also fused V1V2 to an Fc fragment to mimic the unconstrained V1V2 conformation. We tested these V1V2-scaffold proteins for immunogenicity in rabbits and assessed the responses by enzyme-linked immunosorbent assay (ELISA) and competition assays. Our V1V2 immunogens induced distinct conformation-specific Ab responses. Abs induced by structurally unconstrained immunogens reacted preferentially with unconstrained V1V2 antigens, suggesting recognition of the helical configuration, while Abs induced by the structurally constrained immunogens reacted preferentially with constrained V1V2 antigens, suggesting recognition of the β-strand conformation. The Ab responses induced by the structurally constrained immunogens were more broadly reactive and had higher titers than those induced by the structurally unconstrained immunogens. Our results demonstrate that immunogens presenting the different structural conformations of the gp120 V1V2 vulnerable site can be designed and that these immunogens induce distinct Ab responses with epitope conformation specificity. Therefore, these structurally constrained V1V2 immunogens are vaccine prototypes targeting the V1V2 domain of the HIV-1 envelope. IMPORTANCE The correlates analysis of the RV144 HIV-1 vaccine trial suggested that the presence of antibodies to the V1V2 region of HIV-1 gp120 was responsible for the modest protection observed in the trial. In addition, V1V2 harbors one of the key vulnerable sites of HIV-1 Env recognized by a family of broadly neutralizing MAbs such as PG9. Thus, V1V2 is a key target for vaccine development. However, this vulnerable site is structurally polymorphic, and designing immunogens that present different conformations is crucial for targeting this site. We show here that such immunogens can be designed and that they induced conformation-specific antibody responses in rabbits. Our immunogens are therefore prototypes of vaccine candidates targeting the V1V2 region of HIV-1 Env.

22 June 2023 in Journal of Molecular Biology
Verified
Journal Article
Open access
ASAlina P. Sergeeva
Alina P. Sergeeva
PKPhinikoula S. Katsamba
Phinikoula S. Katsamba
JLJunzhuo Liao
Junzhuo Liao
JSJared M. Sampson
Jared M. Sampson
FBFabiana Bahna
Fabiana Bahna
BHBarry Honig
Barry Honig
• Effects of mutations on RBD::ACE2 binding are calculated and tested experimentally. • Free energy perturbation (FEP) produces the most accurate agreement with experiment. • Analysis of FEP trajectories provides physical insights that may be useful in protein design. • FEP simulations offer a way forward in many practical applications of biological importance.